Kymera Therapeutics Inc (KYMR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $116.92 (-1.32%), Market cap $6.76B, 52-week low–high $28.14 ~ $95.03.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of
Financial statements, price targets, institutional (13F) holdings and related news for Kymera Therapeutics Inc are updated in real time on BlackAll Trade.
Kymera Therapeutics Inc trades at $116.92 (-1.32%). Real-time quotes and charts are available on BlackAll Trade.
Kymera Therapeutics Inc has a market cap of about $6.76B.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing